SuperworthIntellia Therapeutics NTLA
- Market cap
- $1.6B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 26.4×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $59.5M
- +13% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −22.2%
Intellia Therapeutics trades at 26.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $59.5M over the last twelve months, up 13% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $12M−10% | n/a | $28.9M+130% | $7M−49% | $9.1M−24% | $12.9M | $16.6M−43% | $14.2M+105% | $13.8M+51% | $23M+79% | $15M−10% | $7.7M−46% | |
| R&D | $113.7M+18% | n/a | $111.8M+15% | $114.2M−1% | $123.4M+9% | $116.9M | $108.4M−3% | $97M−15% | $94.7M−23% | $88.7M−24% | $80.7M−26% | $82.6M−15% |
| SG&A | $29.4M+33% | n/a | $31.1M+13% | $31.8M+4% | $30.5M+4% | $32.4M | $29M−7% | $27.2M−14% | $30.5M+0% | $33.1M+2% | $34.8M+20% | $37.8M+39% |
| −$131.1M+24% | n/a | −$114M+2% | −$139M+5% | −$144.8M+10% | −$136.4M | −$120.8M+6% | −$110M−21% | −$111.5M−23% | −$98.7M−28% | −$100.5M−17% | −$112.8M+3% | |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$122.2M+8% | −$132.2M+17% | −$107.4M+4% | −$147M+19% | −$135.7M+11% | −$128.9M−3% | −$114.3M+6% | −$101.3M−31% | −$101.3M−25% | −$95.8M−26% | −$96.2M−16% | −$106.6M+5% |
| −$1.38−7% | −$1.46+4% | −$1.12−4% | −$1.52+9% | −$1.34−3% | −$1.27−13% | −$1.10−2% | −$0.98−36% | −$0.92−31% | −$0.83−35% | −$0.81−26% | −$0.80−18% | |
| 88.6M+17% | 90.5M+11% | 95.5M+9% | 97M+10% | 101M+14% | 101.8M+13% | 103.5M+8% | 103.7M+7% | 110.2M+9% | 115.9M+14% | 118.5M+15% | 133.5M+29% |
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Intellia Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NTLAIntellia Therapeutics | $1.6B | n/m | n/a | 26.4× | +13% | n/m | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| BLLNBillionToOne | $5.1B | 166× | 151× | 12.8× | +90% | 9.5% | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | 4.2× | +2% | 17.7% | |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | 9.1× | +85% | 10.6% | |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | 3.8× | +1% | 8.6% | |
| Peer median | $5.1B | 44.8× | 35.1× | 6.9× | +17% | 10.6% |
Investors who own it
Investors we follow who held Intellia Therapeutics at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management1.9% of portfolioadded
More on Intellia Therapeutics
Each number over time
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .